Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biondvax Pharma ADR (NQ: BVXV ) N/A UNCHANGED Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biondvax Pharma ADR < Previous 1 2 3 4 5 6 7 8 Next > BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team April 20, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Equity Research Report April 19, 2023 Via Investor Brand Network 12 Health Care Stocks Moving In Wednesday's Pre-Market Session April 19, 2023 Via Benzinga BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports FY 2022 Financial Statements, Corporate Update April 18, 2023 Via Investor Brand Network Exposures COVID-19 Biden Signs Measure to End National COVID-19 Emergency April 17, 2023 Via Investor Brand Network Topics Government Exposures COVID-19 Political Eczema or Asthma Predisposes Individuals to Osteoarthritis April 04, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland April 18, 2023 Via Investor Brand Network BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update April 17, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities April 14, 2023 Via Investor Brand Network New Approach Could Boost Current Asthma Medication Efficacy March 23, 2023 Via Investor Brand Network Risk Factors of Age-Related Macular Degeneration February 27, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring April 14, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies April 03, 2023 Via Investor Brand Network Exposures COVID-19 Scientists Sound Alarm on Climate-Change-Induced Rise of Deadly infections March 29, 2023 Via Investor Brand Network Topics Climate Change Exposures Climate BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants March 24, 2023 Via Investor Brand Network Exposures COVID-19 Japan to Categorize COVID-19 as Common Infectious Illness March 17, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring March 16, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax to Present at BIO-Europe Spring March 16, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Study Shows Air Pollution in Urban Areas Worsens Lung Function in Kids March 13, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders March 13, 2023 Via Investor Brand Network IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman March 06, 2023 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property Climate Change Heightening Risk of Global Infectious Illnesses March 06, 2023 Via Investor Brand Network Topics Climate Change Exposures COVID-19 Climate BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series March 06, 2023 Via Investor Brand Network BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), Collaborators Positioned to Rapidly Develop Neutralizing NanoAbs for Emerging COVID-19 Variants March 03, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies March 02, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants February 24, 2023 Via Investor Brand Network Exposures COVID-19 Product Safety BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal February 22, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages February 15, 2023 Via Investor Brand Network Exposures COVID-19 Study Finds Common Fatty Acid May Increase Pain, Temperature Sensitivity in Psoriasis February 15, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference February 13, 2023 Via Investor Brand Network Exposures COVID-19 < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.